# GPT-5.2 Review

**Role:** External referee review
**Model:** openai/gpt-5.2
**Paper:** paper.pdf
**Timestamp:** 2026-02-18T14:01:01.395217
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 17624 in / 4074 out
**Response SHA256:** 613facad0b398fb8

---

## Referee Report: “The Elasticity of Medicaid's Safety Net: Market Responses to Provider Fraud Exclusions”

### Summary and contribution
The paper asks a clear policy-relevant question: when the federal government excludes a Medicaid provider for fraud (LEIE exclusions), do local markets “absorb” displaced patients via other providers, or do gaps in care persist? The authors’ key empirical innovation is a linkage of the LEIE universe to T-MSIS fee-for-service (FFS) claims (2018–2024), and the paper’s headline “result” is largely a null effect of exclusions on “rest-of-market” (ROM) spending, provider counts, and beneficiaries served in a ZIP × service-category market definition. A second and arguably more robust contribution is documenting an extreme attrition/matching cascade from 82k exclusions to 22 analysable “market events.”

This is a promising start: the data construction is potentially valuable to the field and the question is important. However, as written, the paper’s causal claims are not yet supported strongly enough for a top general-interest journal. The biggest issues are (i) the effective reliance on a TWFE-style event-study/static DiD with staggered timing and heterogeneous effects without a modern DiD estimator (despite citing the literature), (ii) inference with very few treated clusters (16 ZIPs) without using small-sample-robust methods as the primary inference framework, and (iii) interpretability of the ROM outcomes given anticipatory exit and possible billing re-labeling/organizational substitution (“shell” NPIs, affiliates) around exclusion.

My recommendation is **MAJOR REVISION**. The project is salvageable and could become a strong AEJ:EP-type contribution if the authors (a) retool the DiD estimator and inference to meet current standards, (b) tighten the interpretation around what is identified (and what is not) with ROM outcomes, and (c) push more of the paper’s value into a credible descriptive/measurement contribution if causal power remains limited.

---

# 1. Format check

### Length
- The LaTeX source appears consistent with a full-length paper (likely **~30–40 pages** excluding references/appendix, depending on table/figure sizes). **Pass** on length for the target journals.

### References
- The paper cites key DiD/event-study methodology (Callaway & Sant’Anna; Sun & Abraham; Goodman-Bacon; Roth; Rambachan & Roth) and some healthcare/Medicaid literature.
- However, the *domain* literature on (i) provider exits/closures and access, (ii) fraud enforcement impacts, and (iii) network adequacy/managed care would benefit from expansion. See Section 4 below for concrete missing cites and BibTeX.

### Prose
- Introduction, institutional background, strategy, results, discussion are in paragraphs. Bullets are mostly limited to predictions/variable definitions. **Pass**.

### Section depth
- Major sections generally have ≥3 substantive paragraphs. **Pass**.

### Figures
- As LaTeX source, figures are `\includegraphics{...}`. I cannot verify axes/visibility. Do not treat as missing. But note a possible inconsistency: Figure event-study notes say “clustered at the unit level” while text says clustered at ZIP level—needs harmonization.

### Tables
- Tables are input from external `.tex` files (`tab2_main.tex`, etc.). I can’t verify if they contain real numbers, but the text reports coefficients/SEs/CI, suggesting real content. Ensure every regression table reports N, clustering level, and FE structure.

**Format fixes (actionable)**
1. Ensure *every* regression table includes: **N (observations), # clusters, SE clustering level, FE list, and treatment window**.
2. Ensure consistent clustering statement across text, table notes, and figure notes (ZIP vs unit).

---

# 2. Statistical methodology (critical)

### a) Standard errors
- Main text reports coefficients with SEs (e.g., β = −0.026, SE = 0.246). Table notes say “SEs clustered at ZIP level.” **Pass**, conditional on the actual tables containing SEs for all coefficients.

### b) Significance testing
- The paper provides p-values at least for RI and some placebo estimates; star notation in table note. **Pass**.

### c) Confidence intervals
- The paper reports a 95% CI for the main estimate in the text. Event study figure claims 95% bands. **Pass**, but I recommend adding **95% CIs in the main tables** (either as CI columns or in notes) for at least the main outcome.

### d) Sample sizes
- The paper states “N = 22 treated units” and describes unit of observation as ZIP × service × month, but it is not clear that **regression N (rows)** is reported in tables. This is essential. **Potential fail if omitted in tables.** Add: total observations, treated observations, control observations, and clusters.

### e) DiD with staggered adoption (major concern)
- You use an event-study DiD with staggered treatment timing and include unit FE + state×month FE. This is essentially a TWFE/event-study setup. You cite modern staggered-adoption papers but do not clearly implement their estimators.
- With staggered timing, conventional TWFE event studies can be biased when treatment effects are heterogeneous over cohorts/event time (Sun & Abraham 2021; Goodman-Bacon 2021). Your description of controls (“never-treated markets in same state that do not experience any LEIE exclusion in event window”) helps, but it is not fully clear that the estimator **never uses already-treated units as controls** across event times/cohorts.
- The “static” Post specification (equation 2) is particularly vulnerable: with staggered adoption and dynamic effects/anticipation, the Post dummy pools many comparisons.

**This is not a desk-reject-level fatal flaw only because treatment is rare**, but for top journals you must implement a staggered-robust estimator or convincingly argue why TWFE comparisons reduce to clean treated-vs-never-treated within state×month.

**Required fix**
- Re-estimate using at least one of:
  - **Callaway & Sant’Anna (2021)** `att_gt` / aggregated event-study,
  - **Sun & Abraham (2021)** interaction-weighted event study,
  - Optionally: **Borusyak, Jaravel & Spiess (2021)** imputation approach (good with many FE).
- Then show that results are similar to TWFE (if they are). If not, update conclusions.

Also clarify whether controls are:
- truly **never-treated in the entire sample**, or
- **not-yet-treated** (which is the problematic case),
- and what happens if a control becomes treated later.

### f) RDD
- Not applicable.

### Inference with few clusters (critical)
- You cluster at ZIP (16 treated ZIPs; control ZIPs likely many). But treatment variation is concentrated: the relevant effective cluster count for treatment is small. Conventional cluster-robust SEs can be unreliable.
- You do randomization inference (good), but you present it as “supplement.” For a top journal, I recommend making small-sample-robust inference **primary**, e.g.:
  - **Wild cluster bootstrap** (Cameron, Gelbach & Miller) with clustering at ZIP, or at the “market” (ZIP×service) level; report bootstrap p-values and CIs.
  - Consider **randomization inference inversion** to obtain RI-based CIs (not just a p-value).
  - Consider **randomization at the level consistent with assignment** (state×service×time strata), and explain why the RI design matches your identifying variation.

---

# 3. Identification strategy

### Credibility
- The conceptual design—provider exclusion as an abrupt supply shock—is plausible. However, the paper itself documents strong **pre-exclusion decline** in excluded providers’ billing (Figure 3), which is a classic “anticipation/phase-in” problem and undermines the clean “shock at month 0” interpretation.

Your robustness redefining treatment date as billing falling below 50% is helpful, but it raises deeper questions:
- Is the “treatment” the **investigation**, **state actions**, **provider voluntary exit**, or **federal exclusion**?
- If market response begins at investigation onset, then LEIE date may be a noisy proxy; your causal estimand becomes unclear.

**Needed improvements**
1. **Define the estimand precisely**: effect of *federal exclusion date* vs effect of *provider exit from Medicaid billing* (which may precede formal exclusion). Right now the narrative alternates.
2. Provide event studies aligned to:
   - LEIE effective date, and
   - “exit date” (billing collapse)  
   and interpret each.

### Parallel trends
- You show event-study pre-coefficients “centered near zero,” but with wide CIs. Visual checks are fine, but top journals will want:
  - a pre-trend test that is **well-posed** under small N (e.g., fewer leads, or pooled linear pre-trend slope test),
  - and/or Roth (2022/2023) style sensitivity that you cite (you mention HonestDiD in appendix—good; elevate it to the main text with a clear figure/table).

### Placebos/robustness
Good starts:
- placebo service in same ZIP,
- placebo timing 1–3 years before (appendix),
- alternative market share thresholds,
- alternative geography (county),
- RI.

Gaps:
1. **Spillovers are likely first-order**, not just a footnote. If patients travel to adjacent ZIPs or providers shift billing ZIP, your “exclude within 5 miles” rule could remove precisely the area where absorption occurs. Consider explicitly testing for spillovers by:
   - measuring outcomes in rings (0–5 miles excluded; 5–15; 15–30), or
   - defining markets at larger commuting zones / hospital referral regions for some services.
2. **Composition/billing substitution**: Excluded providers might reappear as a different NPI (affiliate/relative/new entity). This could mechanically show up as “ROM absorption.” You allude to this but do not test it. At minimum:
   - Check whether post-exclusion gains are driven by **new NPIs** entering vs incumbents expanding.
   - Examine concentration (HHI) and top-1 share among non-excluded providers pre/post.
3. **Managed care missingness**: Because you use FFS claims, treatment could shift volume into managed care encounters (or vice versa) in ways you cannot observe. At least stratify by states with higher FFS share, or restrict to high-FFS states if feasible, and show robustness.

### Do conclusions follow?
- The paper is admirably cautious, but some wording still risks over-reading the null. In several places you state “markets appear to adjust” or “access concerns may be overstated.” Given CI width and selection into 22 events, those policy claims should be tempered or explicitly framed as *conditional on detectable shocks in FFS markets*.

---

# 4. Literature (missing references + BibTeX)

### (A) Fraud enforcement / exclusions / sanctions
You claim little is known about market effects of exclusions. That may be true, but you should more thoroughly situate this in related sanctions/enforcement literatures (Medicare/Medicaid audits, provider dis-enrollment, opioid pill mill closures, etc.). Even if not exactly LEIE, these are close analogs.

Suggested additions:
1. **Borusyak, Jaravel, Spiess (imputation DiD)** — relevant to your high-dimensional FE, staggered timing, small treated share.
```bibtex
@article{BorusyakJaravelSpiess2021,
  author = {Borusyak, Kirill and Jaravel, Xavier and Spiess, Jann},
  title = {Revisiting Event Study Designs: Robust and Efficient Estimation},
  journal = {Working Paper},
  year = {2021}
}
```
(If you prefer published versions/updates, cite the latest available working paper version; this is widely cited in top-journal submissions.)

2. **Cameron, Gelbach, Miller (wild cluster bootstrap)** — directly relevant for inference with few clusters.
```bibtex
@article{CameronGelbachMiller2008,
  author = {Cameron, A. Colin and Gelbach, Jonah B. and Miller, Douglas L.},
  title = {Bootstrap-Based Improvements for Inference with Clustered Errors},
  journal = {The Review of Economics and Statistics},
  year = {2008},
  volume = {90},
  number = {3},
  pages = {414--427}
}
```

3. **Fisher & Vigdor / or other provider-sanction work**: I’m not certain which exact paper best matches LEIE exclusions; you should search and cite work on Medicare fraud actions and provider exits. If none exists, explicitly say you searched for “LEIE + claims + outcomes” and found none, but cite adjacent work on enforcement/audits (e.g., Medicare RAC audits) if available.

### (B) Modern DiD/event-study practice (you cite some, but add/ensure key ones)
You already cite Callaway & Sant’Anna; Sun & Abraham; Goodman-Bacon; Roth; Rambachan & Roth. Ensure the citations are complete and correctly formatted.

Add:
```bibtex
@article{BakerLarckerWang2022,
  author = {Baker, Andrew C. and Larcker, David F. and Wang, Charles C. Y.},
  title = {How Much Should We Trust Staggered Difference-in-Differences Estimates?},
  journal = {Journal of Financial Economics},
  year = {2022},
  volume = {144},
  number = {2},
  pages = {370--395}
}
```
This is not mandatory, but it’s a common reference motivating robust estimators.

### (C) Provider exit/closure/access literature
You cite Mommaerts (nursing home closures). Add more on provider exits and access/continuity; even if not Medicaid-specific, it strengthens framing.

If you focus on “thin markets” and access, consider citing:
- papers on hospital closures and access,
- Medicaid provider participation and network adequacy,
- HCBS supply constraints.

(I’m not providing BibTeX for these because the exact best citations depend on your precise angle and what you already include in `references.bib`; but I strongly recommend expanding this section with 5–10 more domain citations and explicitly tying your “elasticity” framing to access and capacity constraints.)

---

# 5. Writing quality (critical)

### Strengths
- The paper is readable, well organized, and unusually transparent about limitations and attrition.
- The introduction clearly states the question, data, and the main result, and the “attrition cascade” is a compelling organizing device.

### Areas to improve
1. **Clarify what “elasticity” means empirically.** Your outcomes are *rest-of-market billing*. A null in ROM spending does not map cleanly to “no access harm” vs “full absorption.” You acknowledge observational equivalence, but the paper still sometimes slides into access interpretations. Tighten language so the reader never confuses “billing absorption” with “access maintained.”
2. **Unify the market definition rationale.** ZIP × service is intuitive but ad hoc. Add 1–2 paragraphs explaining why ZIP is reasonable for each major service class (E&M, HCBS, DME, behavioral health), and where it is not.
3. **Reduce repetition.** The attrition cascade is described multiple times (abstract, intro, discussion, conclusion). Keep it, but streamline and point to one canonical figure/table early.

---

# 6. Constructive suggestions to make the paper more impactful

### A. Make the causal design state-of-the-art
1. Replace TWFE event-study with **Sun–Abraham or Callaway–Sant’Anna** event-time effects, plus a static aggregate ATT.
2. Use **wild cluster bootstrap** and/or **RI-inverted CIs** as headline inference.
3. Report **minimum detectable effects (MDEs)** given your design (22 treated units). This will help readers understand what null means.

### B. Turn the “attrition cascade” into a first-class contribution
Right now it is presented as a “finding,” but you could push it further:
1. Decompose attrition by **state**, **service type**, **individual vs entity NPI**, and **mandatory vs permissive** exclusion. This can yield concrete policy insights (“why is match rate 2.3%?”).
2. Provide a systematic comparison of excluded providers who *do* match to T-MSIS vs those who do not (observable characteristics from LEIE/NPPES): taxonomy, geography, entity type. This can become publishable descriptive work even if causal power is limited.
3. Quantify how much **Medicaid spending** the excluded providers represent in the FFS data (share of statewide FFS spending). That’s a strong policy statistic.

### C. Improve interpretation of “absorption”
Absorption rates >1 are striking but ambiguous. To sharpen:
1. Decompose ROM spending change into:
   - incumbent providers’ expansion,
   - entry of new providers (new NPIs not previously billing in that market),
   - shifts in mix of codes (intensity vs extensive margin).
2. Show whether beneficiary counts rise while spending does not (or vice versa), which can indicate intensity changes.
3. Track whether the **excluded provider’s beneficiaries** (identified by beneficiary IDs) reappear with other providers in subsequent months. That would directly measure continuity and avoid market-definition issues. Even a limited version (in-state only, same service category) would be powerful.

### D. Address managed care explicitly
If encounter data are missing/low quality, be direct:
- Stratify states by managed care penetration and show results separately, or
- Limit to high-FFS states and acknowledge external validity.

---

# 7. Overall assessment

### Key strengths
- Important and under-studied policy question.
- Novel linkage of LEIE exclusions to T-MSIS claims, with transparent sample construction.
- Honest discussion of limitations; strong attempt at robustness (placebos, RI, timing).

### Critical weaknesses (must fix)
1. **Estimator validity under staggered adoption:** must use staggered-robust DiD/event-study estimators or convincingly show TWFE is not contaminated by already-treated controls.
2. **Inference with few treated clusters:** cluster-robust SEs are likely unreliable; elevate wild bootstrap/RI-based CIs.
3. **Interpretation of ROM outcomes:** need clearer mapping from ROM billing to market absorption/access, and more checks against billing relabeling/affiliate substitution.

### Specific path to improvement
- Re-estimate main results with Sun–Abraham and/or Callaway–Sant’Anna; report ATT and dynamic effects.
- Provide RI-inverted 95% CIs (or wild bootstrap CIs) and an MDE calculation.
- Add at least one beneficiary-level continuity analysis (even descriptive) and one decomposition of absorption (entry vs expansion).
- Expand domain literature on provider exit/access and enforcement analogs; tighten claims in discussion.

---

DECISION: MAJOR REVISION